THOMAS MONATH to Ebolavirus
This is a "connection" page, showing publications THOMAS MONATH has written about Ebolavirus.
Connection Strength
2.605
-
rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
Score: 0.928
-
Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017 08 16; 35(35 Pt A):4465-4469.
Score: 0.545
-
Transcriptomic signatures induced by the Ebola virus vaccine rVSV?G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. Lancet Microbe. 2022 02; 3(2):e113-e123.
Score: 0.186
-
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Emerg Microbes Infect. 2021 Dec; 10(1):651-663.
Score: 0.185
-
Ecology of Marburg and Ebola viruses: speculations and directions for future research. J Infect Dis. 1999 Feb; 179 Suppl 1:S127-38.
Score: 0.152
-
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018 07; 18(7):738-748.
Score: 0.144
-
Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. Hum Vaccin Immunother. 2018 04 03; 14(4):994-1002.
Score: 0.141
-
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017 10 12; 377(15):1438-1447.
Score: 0.139
-
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 01 26; 376(4):330-341.
Score: 0.117
-
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
Score: 0.034
-
Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
Score: 0.034